Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Highlights IDO1 and TDO2 catalyze the commitment and rate-limiting step of the KYN metabolic pathway that produces the endogenous AhR agonist KYN. Activation of AhR